Vaxcyte

Vaxcyte is a privately held company located in San Carlos, California. With 391 employees, the company focuses on developing innovative vaccines to combat bacterial diseases. Vaxcyte specializes in engineering high-fidelity vaccines using advanced synthetic techniques, including the XpressCFᵀᴹ cell-free protein synthesis platform. Their product pipeline includes VAX-24, a broad-spectrum pneumococcal conjugate vaccine for preventing invasive pneumococcal disease; VAX-XP, a PCV with expanded coverage of over 30 strains; VAX-A1, a prophylactic vaccine candidate for Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate for periodontal disease. The company's unique approach to vaccine development utilizes modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ platform, to create vaccines with enhanced immunological benefits. This cell-free system allows for the efficient production of complex proteins and antigens, accelerating the development and delivery of high-quality vaccines. For more information about Vaxcyte and its innovative vaccine solutions, visit their website at vaxcyte.com.